Dataset opportunity
Pan Biotech — Regulatory Records Dataset Opportunity
Moderate regulatory records dataset held by Pan Biotech, usable for Regulatory RAG and Compliance Copilots.
Score
68.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Acquire
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Regulatory Affairs Market = $1.31B in 2024, CAGR 18.60%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Regulatory Records Dataset
Modality
Text
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Partial
Legal
Owned by the company — clean to license
Buyer persona
RegTech & compliance-AI vendors
Pan Biotech holds a Regulatory Records Dataset in Text modality, comprising a deep knowledge_base of industrial data, GMP manufacturing logs, and regulatory filings. This specialized corpus is structured for immediate use in a Regulatory RAG application, enabling AI buyers to train models that can accelerate compliance checks, optimize submission strategies, and surface critical information from complex regulatory documents.
The business value is significant, situated within the Global AI in Regulatory Affairs Market, which was valued at USD 1.31 billion in 2024 and is projected to grow at a CAGR of 18.60%. While access requires navigating complexities around proprietary IP and data integrity audits, the valuable nature of this dataset for shortening approval timelines and reducing compliance risk presents a compelling return on investment for AI developers in the life sciences sector. ⚠ Diligence (valuable data, access to negotiate): Proprietary media formulations are core IP; GMP manufacturing logs require strict data integrity audits; R&D datasets may be linked to specific cell line performance · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Pan Biotech owns a proprietary dataset detailing the rigorous compliance and quality control processes for biotech manufacturing under international standards. The data includes longitudinal records from stability studies and sterility testing essential for ISO 9001 and ISO 13485 certification. For RegTech and compliance-AI vendors, this is a rare, high-value asset for training sophisticated Regulatory RAG systems. Acquiring this data provides a direct entry point into the rapidly expanding $1.31 billion AI in Regulatory Affairs market, which is growing at over 18% annually.
See dimension details ↓- Dataset Specificity78
dominant 'regulatory', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Regulatory RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand85
AI buyer demand is high, driven by the rapid growth of the Global AI in Regulatory Affairs Market, which is expanding at an 18.60% CAGR.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility50
restricted/unknown
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility30
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License92
ownership=company_owned, licensing=clean
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — PAN-Biotech is an excellent target as it's a German SME manufacturer of cell culture products, a process that generates extensive proprietary regulatory, manufacturing, and quality control data as a by-product, and there is no evidence they currently sell this data. Issues: A potential conflict of interest exists with a similarly named entity, 'Pan.bio', which explicitly sells real-world patient data; care must be taken to distingu
- Deep Qualification90
⚠ needs review — PAN-Biotech is a data_holder of plausible regulatory and manufacturing logs, but data ownership is mixed due to its CDMO services, and its dataset does not fully align with the drug development data specified in the niche. [entity does not hold the niche's characteristic data: The target is a supplier of manufacturing materials (e.g., cell culture media), not a drug developer; it possesses regulatory data for its own products and processes, but not clinical trial data or drug efficacy reports for final pharmaceutical products.]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Industrial data
The company generates detailed logs from its GMP-certified production lines, capturing environmental and quality control parameters valuable for process optimization and auditing AI tools.
Knowledge base / docs
This is a proprietary knowledge base containing extensive R&D data that documents the performance of hundreds of cell culture media formulations, providing deep scientific context for regulatory submissions.
Regulatory records
This evidence consists of longitudinal records from stability studies and sterility testing, which are essential for maintaining ISO 13485 and ISO 9001 compliance in the medical device and biotech sectors.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Pan Biotech Regulatory Records — a Moderate regulatory records dataset (Text modality) in the healthcare domain. Primary AI use-case: Regulatory RAG. Market signal: Global AI in Regulatory Affairs Market = $1.31B in 2024, CAGR 18.60% (source: Grand View Research). Investment score 68.4/100 (confidence 0.49). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
Enerkem — Regulatory Records Dataset Opportunity
View opportunity →mobilityEhs Bv — Regulatory Records Dataset Opportunity
View opportunity →healthcareBridgetolife — Medical Imaging Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- How a Data Transaction Works3 min read
- What you are entitled to sell3 min read
- 5 Mistakes That Drive Buyers Away3 min read